COMP <GO>
CTMX vs OCS // EV/EBITDA & P/E VALUATION
CytomX Therapeutics Inc. (NASDAQ) VS. Oculis Holding AG (NASDAQ) • 15-METRIC TALLY: CTMX 1
— OCS 1
■ METRIC PARITY
LAST: $2.34 (+2.18%) • MKT CAP: $509.9M
valuation
—
LAST: $8.26 (+0.24%) • MKT CAP: $508.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTMX VS. OCS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTMX | OCS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.19% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -29.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -22.80% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -44.80% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.5 | 45.7 | -2.20 | OCS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $509.9M | $508.7M | $1.2M | CTMX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTMX REV | OCS REV | CTMX GROSS % | OCS GROSS % | CTMX FCF | OCS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $76.2M | — | — | — | -$75.8M | — |
| FY 2024 | $138.1M | — | — | — | -$86.5M | — |
| FY 2023 | $101.2M | — | — | — | -$56.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTMX // BETA —
OCS // BETA —